Fowler CJ, Dalton C, Panicker JN. Review of neurologic diseases for the urologist. Urol Clin North Am. 2010;37:517–26.

Article  Google Scholar 

Mete UK, Powell CR. Review of current neurogenic bladder best practices and international guidelines. Curr Bladder Dysfunct Rep. 2020;15:283–95.

Article  Google Scholar 

Cooley LF, Kielb S. A review of botulinum toxin a for the treatment of neurogenic bladder. Pmr. 2019;11:192–200.

Google Scholar 

Kashyap M, Tyagi P. The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert Opin Drug Metab Toxicol. 2013;9:617–27.

CAS  Article  Google Scholar 

El Helou E, Labaki C, Chebel R, El Helou J, Abi Tayeh G, Jalkh G, et al. The use of mirabegron in neurogenic bladder: a systematic review. World J Urol. 2020;38:2435–42.

Article  Google Scholar 

Wöllner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord. 2016;54:78–82.

Article  Google Scholar 

Welk B, Hickling D, McKibbon M, Radomski S, Ethans K. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2018;37:2810–7.

CAS  Article  Google Scholar 

Krhut J, Borovička V, Bílková K, Sýkora R, Míka D, Mokriš J, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2018;37:2226–33.

CAS  Article  Google Scholar 

Zachariou A, Filiponi M, Baltogiannis D, Giannakis J, Dimitriadis F, Tsounapi P, et al. Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron. Can J Urol. 2017;24:9107–13.

PubMed  Google Scholar 

Chen SF, Kuo HC. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. Low Urin Tract Symptoms. 2019;11:O53–8.

CAS  Article  Google Scholar 

Matsuo T, Miyata Y, Nakamura T, Satoh K, Sakai H. Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy. Low Urin Tract Symptoms. 2019;11:O65–70.

CAS  Article  Google Scholar 

Park JS, Lee YS, Lee CN, Kim SH, Kim SW, Han SW. Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. World J Urol. 2019;37:1665–70.

CAS  Article  Google Scholar 

Stohrer M, Blok B, Castro-Diaz D, Chartier-Kastler E, Del Popolo G, Kramer G, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009;56:81–8.

Article  Google Scholar 

Madersbacher H, Murtz G, Stohrer M. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics. Spinal Cord. 2013;51:432–41.

CAS  Article  Google Scholar 

Przydacz M, Chlosta P, Corcos J. Recommendations for urological follow-up of patients with neurogenic bladder secondary to spinal cord injury. Int Urol Nephrol. 2018;50:1005–16.

Article  Google Scholar 

Kreydin E, Welk B, Chung D, Clemens Q, Yang C, Danforth T, et al. Surveillance and management of urologic complications after spinal cord injury. World J Urol. 2018;36:1545–53.

Article  Google Scholar 

Zhang D, Sun F, Yao H, Bao X, Wang D, Cui Y, et al. The efficacy and safety of mirabegron for the treatment of neurogenic lower urinary tract dysfunction: a systematic review and meta-analysis. Front Pharmacol. 2021;12:756582.

CAS  Article  Google Scholar 

Cho SY, Jeong SJ, Lee S, Kim J, Lee SH, Choo MS, et al. Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson’s disease: a double-blind, randomized placebo-controlled trial (Parkinson’s Disease Overactive bladder Mirabegron, PaDoMi Study). Neurourol Urodyn. 2021;40:286–94.

Article  Google Scholar 

Brucker BM, Kalra S. Parkinson’s disease and its effect on the lower urinary tract: evaluation of complications and treatment strategies. Urol Clin North Am. 2017;44:415–28.

Article  Google Scholar 

Gray R, Stern G, Malone-Lee J. Lower urinary tract dysfunction in Parkinson’s disease: changes relate to age and not disease. Age Ageing. 1995;24:499–504.

CAS  Article  Google Scholar 

Vurture G, Peyronnet B, Palma JA, Sussman RD, Malacarne DR, Feigin A, et al. Urodynamic mechanisms underlying overactive bladder symptoms in patients with Parkinson disease. Int Neurourol J. 2019;23:211–8.

Article  Google Scholar 

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.

Article  Google Scholar 

Glykas I, Fragkoulis C, Mitsikostas DD, Papatsoris A, Mitsogiannis I, Papadopoulos G, et al. B3 agonists or anticholinergics in the treatment of the lower urinary tract dysfunction in patients with multiple sclerosis? A randomized study. World J Urol. 2021;39:3049–56.

CAS  Article  Google Scholar 

Vasudeva P, Prasad V, Yadav S, Kumar N, Saurav K, Prashanth YM, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity resulting from traumatic spinal cord injury: a prospective study. Neurourol Urodyn. 2021;40:666–71.

CAS  Article  Google Scholar 

Trbovich M, Romo T, Polk M, Koek W, Kelly C, Stowe S, et al. The treatment of neurogenic lower urinary tract dysfunction in persons with spinal cord injury: an open label, pilot study of anticholinergic agent vs. mirabegron to evaluate cognitive impact and efficacy. Spinal Cord Ser Cases. 2021;7:50.

Article  Google Scholar 

Brucker BM, Jericevic D, Rude T, Enemchukwu E, Pape D, Rosenblum N, et al. Mirabegron versus Solifenacin in multiple sclerosis patients with overactive bladder symptoms: a prospective comparative nonrandomized study. Urology. 2020;145:94–9.

Article  Google Scholar 

Krebs J, Pannek J, Rademacher F, Wöllner J. Real-world effects of mirabegron in patients with chronic neurogenic detrusor overactivity—a retrospective cohort study. Res Rep Urol. 2020;12:187–92.

CAS  PubMed  PubMed Central  Google Scholar 

Han SH, Cho IK, Jung JH, Jang SH, Lee BS. Long-term efficacy of mirabegron add-on therapy to antimuscarinic agents in patients with spinal cord injury. Ann Rehabil Med. 2019;43:54–61.

Article  Google Scholar 

Krhut J, Wohlfahrt P, Pudich J, Kufová E, Borovička V, Bílková K, et al. Cardiovascular safety of mirabegron in individuals treated for spinal cord injury- or multiple sclerosis-induced neurogenic detrusor overactivity. Int Urol Nephrol. 2021;53:1089–95.

Article  Google Scholar 

McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 1981;126:205–9.

CAS  Article  Google Scholar 

Hadiji N, Previnaire JG, Benbouzid R, Robain G, Leblond C, Mieusset R, et al. Are oxybutynin and trospium efficacious in the treatment of detrusor overactivity in spinal cord injury patients? Spinal Cord. 2014;52:701–5.

CAS  Article  Google Scholar 

Yamano Y, Sato T. Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis. Front Microbiol. 2012;3:389.

CAS  Article  Google Scholar